期刊文献+

神经母细胞瘤患儿骨髓PHOX2B基因临床意义探讨 被引量:1

Clinical significance of PHOX2B in bone marrow of patients with neuroblastoma
下载PDF
导出
摘要 目的探究神经母细胞瘤(NB)患儿骨髓中PHOX2B基因表达的临床意义。方法回顾性分析2020年10月—2022年5月我院血液肿瘤科收治的47例新诊断NB患儿的临床资料,病初检测47例NB患儿骨髓PHOX2B mRNA的表达水平。结果(1)纳入研究的47例NB患儿男26例(55%),女21例(45%);中位发病年龄23.0(0.27-144)个月;INRG临床分期L1期3例(6%)、L2期15例(32%)、M期29例(62%);危险度分组极低危3例(6%)、低危9例(19%)、中危8例(17%)、高危27例(57%);病初存在骨髓转移者(骨髓形态学阳性)20例(43%),骨髓多色流式细胞术(MFC)检测阳性23例(49%),骨髓PHOX2B mRNA表达阳性31例(66%),其中3例体征存在浣熊眼的患儿PHOX2B mRNA水平均显著增高,与内参基因ABL比值分别为58%、75%、117%。(2)PHOX2B阳性组与阴性组在各种首发临床表现方面均无差异(P均>0.05);(3)PHOX2B mRNA表达水平与初诊时的骨髓细胞形态学、MFC计数结果、初诊血NSE值、初诊血LDH值、INRG分期、MYCN基因、危险度分组均具有相关性(P均<0.05)。(4)20例PHOX2B阳性组NB患儿化疗2个疗程后骨髓PHOX2B表达水平、MFC计数结果及骨髓细胞形态学阳性率较病初均明显下降(P均<0.001)。结论骨髓PHOX2B mRNA检测对于NB具有良好的特异性,可反映NB患儿体内肿瘤负荷及判断其危险度,具有一定的临床实用价值。 Objective To investigate the clinical significance of PHOX2B mRNA expression in bone marrow of children with Neuroblastoma(NB).Methods A total of 47 newly diagnosed NB children admitted to the Department of Hematology and Oncology,Children′s Hospital Affiliated to Zhengzhou University from October 2020 to May 2022 were selected as the research objects.The clinical data of patients were collected,and the amount of PHOX2B mRNA expression in the bone marrow of 47 NB children were detected at the beginning of the disease.Results(1)A total of 47 children with NB were included in the study,including 26 males(55.3%)and 21 females(44.7%);The median age of disease onset was 23.0 months(0.27-144 months);The clinical stages of International Neuroblastoma Risk Group(INRG)were 3 cases in stage L1(6.4%),15 cases in stage L2(31.9%),and 29 cases in stage M(61.7%).The risk groups were 3 cases(6.4%)in very low-risk group,9 cases(19.1%)in low-risk group,8 cases(17.0%)in medium-risk group and 27 cases(57.4%)in high-risk group.There were 20 cases(42.6%)with bone marrow metastasis(positive bone marrow cell morphology),23 cases(48.9%)with positive bone marrow MFC and 31 cases(66.0%)with positive expression of bone marrow PHOX2B mRNA at the beginning of the disease.The amount of PHOX2B mRNA expression in 3 children with raccoon eyes was significantly increased,and the ratios of PHOX2B mRNA to the reference gene ABL were 58.4%,74.6%and 116.6%,respectively.(2)There were no significant differences in various initial clinical manifestations between PHOX2B positive group and negative group(all P>0.05).(3)The amount of PHOX2B mRNA expression was correlated with bone marrow cell morphology at first diagnosis,MFC results,neuron specific enolase(NSE)levels at first diagnosis,lactate dehydrogenase(LDH)levels at first diagnosis,INRG stage,MYCN gene and risk group(P<0.05).(4)The amount of PHOX2B mRNAexpression,the results of MFC count and positive rate of bone marrow cell morphology of 20 cases in PHOX2B positive group were significantly decreased compared with the beginning of the disease(P<0.001).Conclusions The detection of PHOX2B mRNA in bone marrow has good specificity for NB,which can reflect the tumor load and estimate the risk of NB in children,it has certain clinical practical value.
作者 臧博伦 刘炜 魏昂 王希思 王天有 李彦格 周崇臣 ZANG Bolun;LIU Wei;WEI Ang;WANG Xisi;WANG Tianyou;LI Yange;ZHOU Chongchen(Department of Hematology and Oncology,Children′s Hospital Affiliated to Zhengzhou University,Department of Hematology and Oncology,Henan Children′s Hospital,Institute of Pediatrics,Henan Children′s Hospital,Zhengzhou 450018,China;Hematological Tumor Center,Beijing Children′s Hospital,Capital Medical University,Beijing 100045,China)
出处 《中国小儿血液与肿瘤杂志》 CAS 2023年第1期9-15,共7页 Journal of China Pediatric Blood and Cancer
关键词 神经母细胞瘤 骨髓 PHOX2B 临床意义 Neuroblastoma Bone marrow PHOX2B Clinical significance
  • 相关文献

参考文献3

二级参考文献22

  • 1Howlader N, Noone AM, Krapcho M, et al, eds. SEER statistics review, 1975-2009 ( Vintage 2009 Populations)[M]. Bethesda, Md: National Cancer Institute, 2012.
  • 2Homer M J, Ries LA, Krapcho M, et al. SEER cancer statistics review, 1975-2006[M]. Bethesda, Md: National Cancer Institute, 2009.
  • 3Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, andresponse to treatment[J]. J Clin Oncol, 1993, 11 (8): 1466- 1477.
  • 4Shimada H,Ambros IM, Dehner LP, et al. The Ivtemational Neuroblastoma Pathology Classification (the Shimada system) [J]. Cancer,1999,86 (2) : 364-372.
  • 5Peuchmaur M Amore ES, Joshi VV, et al. Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular [J ]. Cancer, 2003, 98 (10) : 2274-2281.
  • 6Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report [J]. J Clin Oncol , 2009, 27 (2): 298-303.
  • 7Brisse HJ,McCarville MB, Granata C, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project[D]. Radiology, 2011, 261 (1) : 243-257.
  • 8Brodeur GM,Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment[J]. J Clin Oncol, 1993,11 (8) : 1466- 1477.
  • 9Strother DR,London WB, Schmidt ML, et al. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641[J]. J Clin Oncol , 2012, 30 (15) : 1842-1848.
  • 10Baker DL, Schmidt ML, Cohn SL, et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma[J]. N Engl J Med, 2010,363 (14): 1313-1323.

共引文献93

同被引文献8

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部